Your browser doesn't support javascript.
The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society.
Nagase, Hiroyuki; Nishimura, Yoshihiro; Matsumoto, Hisako; Sugimoto, Naoya; Iwanaga, Takashi; Sano, Akiko; Konno, Satoshi; Hizawa, Nobuyuki; Asano, Koichiro; Horiguchi, Takahiko; Yokoyama, Akihito.
  • Nagase H; Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan. Electronic address: nagaseh@med.teikyo-u.ac.jp.
  • Nishimura Y; Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Matsumoto H; Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Sugimoto N; Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Iwanaga T; Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Sano A; Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Konno S; Department of Respiratory Medicine, Hokkaido University Faculty of Medicine, Sapporo, Japan.
  • Hizawa N; Department of Pulmonary Medicine, University of Tsukuba, Tsukuba, Japan.
  • Asano K; Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan.
  • Horiguchi T; Department of Respiratory Medicine and Clinical Allergy, Fujita Health University, Aichi, Japan.
  • Yokoyama A; Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kochi, Japan.
Respir Investig ; 59(5): 679-682, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1309378
ABSTRACT
There is a concern that persons with underlying respiratory disease may have increased susceptibility to COVID-19 and/or increased severity/mortality if infected. However, information regarding such patients during the first wave of the epidemic is lacking in Japan. We surveyed chest physicians nationwide, and collected anonymous data concerning 1444 patients. Among COVID-19 patients, the prevalence of asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung diseases (ILD) was 3.4%, 4.8%, and 1.5%, respectively. Among COVID-19 patients with these 3 comorbidities, exacerbation of the comorbidity occurred in 12.2%, 18.8%, and 36.4%, respectively, and mortality (6.2% overall) was 4.1%, 13.0%, and 31.8%, respectively. The prevalence of asthma among COVID-19 patients was not higher than that for the general population, and mortality in COVID-19 patients with asthma was not higher than mortality in COVID-19 patients without underlying respiratory disease. COVID-19 patients having COPD or ILD had relatively high mortality, especially for ILD.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiration Disorders / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Country/Region as subject: Asia Language: English Journal: Respir Investig Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiration Disorders / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid Limits: Humans Country/Region as subject: Asia Language: English Journal: Respir Investig Year: 2021 Document Type: Article